BackReata Pharmaceuticals Overview

Reata Pharmaceuticals Other Current Assets

Track Reata Pharmaceuticals's other current assets ($46M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$46.03M
372.65% YoYΔ $36.29M vs prior year quarter

Peer average / median

Loading

Reata Pharmaceuticals Other Current Assets History

Loading

Reata Pharmaceuticals vs. peers: Other Current Assets Comparison

Loading

Reata Pharmaceuticals Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Reata Pharmaceuticals (RETA) FAQ

Reata Pharmaceuticals (RETA) currently reports a other current assets of $46M as of June 2023. That compares with $9.7M in the prior-year period — up 372.6% year over year. Use the charts on this page to explore Reata Pharmaceuticals's other current assets history and peer comparisons.

Reata Pharmaceuticals's other current assets increased from $9.7M to $46M — a 372.6% year-over-year increase (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Reata Pharmaceuticals reported $46M in other current assets as of June 2023. That compares with $9.7M in the prior-year period — up 372.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current assets of $46M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Reata Pharmaceuticals, and consider following RETA for alerts when major investors trade the stock.

Reata Pharmaceuticals is classified in the Healthcare sector. On other current assets, it currently shows $46M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RETA with unrelated industries.